|
|
|
FPRX - Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (FPRX) is a clinical-stage biotechnology company that focuses on developing innovative therapies that target cancer and autoimmune disorders. The company's proprietary platform focuses on identifying and validating novel targets for therapeutics in cancer, inflammation, and other diseases.
Five Prime's lead product candidate, FPA150, is a first-in-class antibody that targets B7-H4, a checkpoint inhibitor that regulates the immune system. The drug is being evaluated in a Phase 1 trial in patients with solid tumors. In addition to FPA150, Five Prime has several other product candidates in various stages of development, including FPA154, FPA157, and FPT155, which target different checkpoint pathways.
Founded in 2002, Five Prime Therapeutics is headquartered in South San Francisco, California. The company has collaborations with multiple pharmaceutical and biotech companies, including Bristol-Myers Squibb and Zai Lab, and has received funding from government agencies such as the National Institutes of Health.
|
|
|
|
|
